The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry.
Gregory A. Daniels
Consultant or Advisory Role - Prometheus
Michael Morse
Consultant or Advisory Role - Prometheus
Michael K.K. Wong
Consultant or Advisory Role - Prometheus
Howard Kaufman
Consultant or Advisory Role - Prometheus
David F. McDermott
Consultant or Advisory Role - Prometheus
Sandra Aung
Employment or Leadership Position - Prometheus
James N. Lowder
Employment or Leadership Position - Prometheus